|Articles|February 1, 2007
eShowcase: ComplianceWire
Enhancements to workplace planning tool include "what if" scenario capability
Advertisement
Enhancements to workplace planning tool include "what if" scenario capability
EduNeering (Princeton, NJ) has added several functionalities to ComplianceWire, its knowledge management system designed for FDA-regulated businesses. Key enhancements include a workplace planning tool researchers can use to create "what if" scenarios for determining job qualifications, planning for future growth, vacation scheduling, and cross training.
Other new capabilities include electronic sign-in for instructor-lead courses, eliminating paper-based systems, and providing a layer of authentication to monitor attendance and streamline recordkeeping. The new User Group format allows administrators to organize and manage employee qualifications, career goals, and other role-based activities. They can then suggest knowledge criteria and curricula based on employee qualifications.
EduNeering, (609) 627-5300, www.eduneering.com
Articles in this issue
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
- Q&A: Strategies for Successful Global Clinical Trial Delivery
September 12th 2025
- Vabysmo Shows Long-Term Efficacy and Safety in Wet AMD, PCV Patients
September 12th 2025
- Latest NIMBLE Study Results Highlight Progress in gMG Research
September 12th 2025
- ACT Brief Episode 8: Expert Insights on the Future of Obesity Drug Trials
September 11th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Phase III BRUIN CLL-313 Trial Finds Jaypirca Extends Progression-Free Survival in Treatment-Naïve CLL/SLL
2
Latest NIMBLE Study Results Highlight Progress in gMG Research
3
ACT Brief Episode 8: Expert Insights on the Future of Obesity Drug Trials
4
FDA Fast Tracks Sanofi’s Intravitreal Gene Therapy for Neovascular Age-Related Macular Degeneration
5